Propel Bio Management’s Regenxbio RGNX Stock Holding History

Propel Bio Management’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-116,896	Closed	-$1.68M	–	40
2025 Q4	$1.68M	Buy	+116,896	New	+$1.46M	1.44%	15

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

IHAM

Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Propel Bio Management's RGNX Position: Q1 2026 in Review

Propel Bio Management sold out of Regenxbio (RGNX) in Q1 2026, closing a stake of 116,896 shares — an estimated $1.68M sold.

Propel Bio Management first reported a position in RGNX in Q4 2025 and held it in 1 quarter. The position peaked at $1.68M in Q4 2025. 178 funds tracked by Wall St. Rank hold RGNX as of Q1 2026.

Propel Bio Management reported no remaining Regenxbio position as of Q1 2026 after selling out during the quarter.
Propel Bio Management sold 116,896 Regenxbio shares in Q1 2026, an estimated $1.68M.
Propel Bio Management first reported a position in Regenxbio in Q4 2025 and held it in 1 quarter.
Propel Bio Management's Regenxbio position peaked at $1.68M in Q4 2025.
178 funds tracked by Wall St. Rank held Regenxbio as of Q1 2026.

Based on Propel Bio Management's 13F filing for Q1 2026, filed 14 May 2026.